|
Factors
|
N = 100
|
|---|
|
Sex (M/F)
|
73 / 27
|
|
Age (< 65/≥65 years)
|
41 / 59
|
|
Tumor size (< 60/≥60 mm)
|
48 / 52
|
|
Histologic type (Diff/Undiff)
|
35 / 65
|
|
pT (1/2/3/4)
|
5 / 12 / 41 / 42
|
|
pN (0/1/2/3)
|
14 / 25 / 31 / 30
|
|
pStage (II/III)
|
39 / 61
|
|
Lymphatic invasion (+/−)
|
80 / 20
|
|
Venous invasion (+/−)
|
78 / 22
|
|
pNLR (+/−)
|
50 / 50
|
|
iNLR (+/−)
|
26 / 74
|
|
fNLR (+/−)
|
38 / 62
|
|
pPLR (+/−)
|
50 / 50
|
|
iPLR (+/−)
|
50 / 50
|
|
fPLR (+/−)
|
35 / 65
|
|
Recurrence (+/−)
|
35 / 65
|
|
Site of relapse (H/P/LYM/Lo)
|
6 / 12 / 17 / 2
|
|
Outcome (D/A)
|
24 / 76
|
- M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR or pPLR, preoperative neutrophil or platelet-to-lymphocyte ratio; iNLR and iPLR, the ratio of the NLR or PLR on the initial day of adjuvant chemotherapy to the pNLR or pPLR; fNLR and fPLR, the ratio of the NLR or PLR on the final day of adjuvant chemotherapy to the iNLR or iPLR; H, hematogenous metastasis; P, peritoneal metastasis; LYM, lymph node metastasis; Lo, local recurrence; D/A, dead or alive
